165 related articles for article (PubMed ID: 26076776)
1. Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.
Jasar D; Smichkoska S; Kubelka K; Filipovski V; Petrushevska G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):69-79. PubMed ID: 26076776
[TBL] [Abstract][Full Text] [Related]
2. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
3. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
4. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.
Doval DC; Sharma A; Sinha R; Kumar K; Dewan AK; Chaturvedi H; Batra U; Talwar V; Gupta SK; Singh S; Bhole V; Mehta A
Asian Pac J Cancer Prev; 2015; 16(12):4959-64. PubMed ID: 26163622
[TBL] [Abstract][Full Text] [Related]
6. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
7. Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Kim MC; Choi JE; Lee SJ; Bae YK
Ann Surg Oncol; 2016 Oct; 23(11):3524-3530. PubMed ID: 27278204
[TBL] [Abstract][Full Text] [Related]
8. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and
the correlation among them].
Li X; Wang Q; Fu L; Liu M; Yu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
[TBL] [Abstract][Full Text] [Related]
9. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
10. Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis.
Payandeh M; Sadeghi M; Sadeghi E; Madani SH
Asian Pac J Cancer Prev; 2016; 17(3):1261-4. PubMed ID: 27039757
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors on the Positivity for Metastases of the Axillary Lymph Nodes from Primary Breast Cancer.
Kondov B; Kondov G; Spirovski Z; Milenkovikj Z; Colanceski R; Petrusevska G; Pesevska M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):81-90. PubMed ID: 28593885
[TBL] [Abstract][Full Text] [Related]
12. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers - Correlation with Morphological and Clinico-Pathological Parameters.
Kolečková M; Kolář Z; Ehrmann J; Kořínková G; Zlámalová N; Melichar B; Trojanec R
Klin Onkol; 2019; 32(5):380-387. PubMed ID: 31610672
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
15. Association of p53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma.
Qamar S; Khokhar MA; Farooq S; Ashraf S; Humayon WA; Rehman A
J Coll Physicians Surg Pak; 2019 Feb; 29(2):164-167. PubMed ID: 30700357
[TBL] [Abstract][Full Text] [Related]
16. Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma.
Chu Z; Lin H; Liang X; Huang R; Tang J; Bao Y; Jiang J; Zhan Q; Zhou X
Jpn J Clin Oncol; 2015 Jul; 45(7):637-41. PubMed ID: 25862826
[TBL] [Abstract][Full Text] [Related]
17. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status.
Shen S; Sun Q; Liang Z; Cui X; Ren X; Chen H; Zhang X; Zhou Y
PLoS One; 2014; 9(6):e100664. PubMed ID: 24945253
[TBL] [Abstract][Full Text] [Related]
18. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
Vane MLG; van Nijnatten TJA; Nelemans PJ; Lobbes MBI; van Roozendaal LM; Kooreman LFS; Keymeulen KBMI; Smidt ML; Schipper RJ
Eur J Surg Oncol; 2019 Apr; 45(4):573-577. PubMed ID: 30732971
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
20. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Pan Y; Yuan Y; Liu G; Wei Y
PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]